CN105530924A - 用卤代烷基胺减少神经元细胞死亡的方法 - Google Patents

用卤代烷基胺减少神经元细胞死亡的方法 Download PDF

Info

Publication number
CN105530924A
CN105530924A CN201480048767.XA CN201480048767A CN105530924A CN 105530924 A CN105530924 A CN 105530924A CN 201480048767 A CN201480048767 A CN 201480048767A CN 105530924 A CN105530924 A CN 105530924A
Authority
CN
China
Prior art keywords
pharmaceutical composition
haloalkylamine
tbi
subject
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480048767.XA
Other languages
English (en)
Chinese (zh)
Inventor
D·J·波尔森
T·F·劳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Montana Missoula
Original Assignee
University of Montana Missoula
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Montana Missoula filed Critical University of Montana Missoula
Priority to CN201910642934.8A priority Critical patent/CN110251496A/zh
Publication of CN105530924A publication Critical patent/CN105530924A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480048767.XA 2013-09-06 2014-09-08 用卤代烷基胺减少神经元细胞死亡的方法 Pending CN105530924A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910642934.8A CN110251496A (zh) 2013-09-06 2014-09-08 用卤代烷基胺减少神经元细胞死亡的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361874865P 2013-09-06 2013-09-06
US61/874,865 2013-09-06
PCT/US2014/054569 WO2015035308A2 (en) 2013-09-06 2014-09-08 Method of reducing neuronal cell death with haloalkylamines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910642934.8A Division CN110251496A (zh) 2013-09-06 2014-09-08 用卤代烷基胺减少神经元细胞死亡的方法

Publications (1)

Publication Number Publication Date
CN105530924A true CN105530924A (zh) 2016-04-27

Family

ID=52629091

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480048767.XA Pending CN105530924A (zh) 2013-09-06 2014-09-08 用卤代烷基胺减少神经元细胞死亡的方法
CN201910642934.8A Pending CN110251496A (zh) 2013-09-06 2014-09-08 用卤代烷基胺减少神经元细胞死亡的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910642934.8A Pending CN110251496A (zh) 2013-09-06 2014-09-08 用卤代烷基胺减少神经元细胞死亡的方法

Country Status (7)

Country Link
US (3) US20160220515A1 (https=)
EP (1) EP3041465B1 (https=)
JP (3) JP6475733B2 (https=)
CN (2) CN105530924A (https=)
CA (1) CA2923476C (https=)
MX (1) MX376515B (https=)
WO (1) WO2015035308A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3041465B1 (en) * 2013-09-06 2020-11-11 The University Of Montana Method of reducing neuronal cell death with haloalkylamines

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007793A1 (en) * 1995-08-29 1997-03-06 New York Medical College Formulations of haloalkylamines and local anaesthetics and methods for the treatment of reflex sympathetic dystrophy (rsd)
US20040063612A1 (en) * 2002-09-26 2004-04-01 Manssur Yalpani Neuroprotective agents
US20060128719A1 (en) * 2004-12-13 2006-06-15 Boehringer Ingelheim Pharmaceuticals, Inc. Use of alpha-adrenergic blockers for the treatment of dysmenorrhea
US20090197969A1 (en) * 2006-08-23 2009-08-06 Poulsen David J Method of reducing brain cell damage or death
CN102946896A (zh) * 2010-04-30 2013-02-27 西安大略大学 Sox9抑制剂

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5513661A (en) 1993-10-14 1996-05-07 Hubbard; David R. Use of sympathetic blockade for treatment of chronic muscle pain
US6009875A (en) 1993-10-14 2000-01-04 Berlex Laboratories, Inc. Use of sympathetic antagonists for treatment of chronic muscle pain
EP1235563A2 (en) 1998-08-26 2002-09-04 Queen's University At Kingston Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
CA2416650C (en) 2000-07-19 2010-09-21 Pitmy International N.V. Enhancement of the action of central and peripheral nervous system agents
US6730667B2 (en) 2001-11-26 2004-05-04 William R. Deagle Iontophoresis disc pain blocker
US7172614B2 (en) * 2002-06-27 2007-02-06 Advanced Cardiovascular Systems, Inc. Support structures for embolic filtering devices
US7600349B2 (en) * 2003-02-26 2009-10-13 Unirac, Inc. Low profile mounting system
WO2007057508A2 (en) 2005-11-18 2007-05-24 Orion Corporation Treatment of pain with a combination of an alpha2 -adrenoceptor antagonist such as atipemezole or fipamezoiie and an opioid receptor agonist, such as tramadol
WO2007062862A2 (en) 2005-12-02 2007-06-07 Ludwig Maximilians Universität München Use of calmodulin inhibitors for the treatment of neurodegenerative disorders
US20070249725A1 (en) 2006-02-17 2007-10-25 Hubbard David R Pharmaceutical formulations of sympathetic antagonist for the treatment of chronic muscle pain
MX2009001966A (es) 2006-08-23 2009-06-19 Univ Montana Metodo de reduccion del daño celular neuronal.
US20110105621A1 (en) * 2006-08-23 2011-05-05 The University Of Montana Method of reducing brain cell damage, inflammation or death
ES2475193T3 (es) 2007-01-22 2014-07-10 Gtx, Inc. Agentes de unión al receptor nuclear
US8292830B2 (en) 2007-05-22 2012-10-23 University Of Louisville Research Foundation, Inc. Soft tissue impact assessment device and system
WO2010148519A1 (en) 2009-06-25 2010-12-29 Queen's University At Kingston Methods and therapies for alleviating pain comprising an ultra low dose of an alpha 2 receptor antagonist
WO2012074561A2 (en) 2010-11-30 2012-06-07 Columbia Northwest Pharmaceuticals Llc Methods and compositions for the treatment of anxiety disorders, including post traumatic stress disorder (ptsd) and related central nervous system (cns) disorders
EP2466311A1 (en) 2010-12-17 2012-06-20 Roche Diagnostics GmbH sFlt1 in patients with ischemic stroke
CA2768796A1 (en) 2011-02-22 2012-08-22 Wellspring Pharmaceutical Corporation Phenoxybenzamine assay
WO2012162364A1 (en) * 2011-05-23 2012-11-29 New York Medical College Phenoxybenzamine for pain
US20140371322A1 (en) 2013-06-13 2014-12-18 Professional Compounding Centers Of America Phenoxybenzamine Transdermal Composition
EP3041465B1 (en) 2013-09-06 2020-11-11 The University Of Montana Method of reducing neuronal cell death with haloalkylamines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007793A1 (en) * 1995-08-29 1997-03-06 New York Medical College Formulations of haloalkylamines and local anaesthetics and methods for the treatment of reflex sympathetic dystrophy (rsd)
US20040063612A1 (en) * 2002-09-26 2004-04-01 Manssur Yalpani Neuroprotective agents
US20060128719A1 (en) * 2004-12-13 2006-06-15 Boehringer Ingelheim Pharmaceuticals, Inc. Use of alpha-adrenergic blockers for the treatment of dysmenorrhea
US20090197969A1 (en) * 2006-08-23 2009-08-06 Poulsen David J Method of reducing brain cell damage or death
CN102946896A (zh) * 2010-04-30 2013-02-27 西安大略大学 Sox9抑制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王忠诚: "《神经外科疾病临床诊疗规范教程》", 31 January 2008 *

Also Published As

Publication number Publication date
WO2015035308A3 (en) 2015-10-29
MX2016002655A (es) 2016-06-06
JP2019077718A (ja) 2019-05-23
EP3041465B1 (en) 2020-11-11
JP6636660B2 (ja) 2020-01-29
JP6865806B2 (ja) 2021-04-28
EP3041465A4 (en) 2017-03-08
US20210093586A1 (en) 2021-04-01
CN110251496A (zh) 2019-09-20
JP2016529320A (ja) 2016-09-23
EP3041465A2 (en) 2016-07-13
US20190083423A1 (en) 2019-03-21
CA2923476A1 (en) 2015-03-12
US10849865B2 (en) 2020-12-01
WO2015035308A2 (en) 2015-03-12
US20160220515A1 (en) 2016-08-04
JP2020059746A (ja) 2020-04-16
MX376515B (es) 2025-03-07
CA2923476C (en) 2021-03-16
JP6475733B2 (ja) 2019-02-27

Similar Documents

Publication Publication Date Title
Sikiric et al. Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications
Moran et al. Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field
ES2750728T3 (es) Uso de cannabinoides en combinación con Aripriprazol
Goldbach-Mansky Current status of understanding the pathogenesis and management of patients with NOMID/CINCA
US20040209850A1 (en) Methods of treating pain and compositions for use therefor
JP2021526507A (ja) 発作により誘発される突然死を処置するための組成物および方法
BR112012005044B1 (pt) Composição farmacêutica que compreende uma combinação de (rac)-tramadol·hcl e celecoxib
Li et al. Contribution of the P2X4 receptor in rat hippocampus to the comorbidity of chronic pain and depression
BR112019020798A2 (pt) métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3
AU2017326013A1 (en) Use of pridopidine for treating Rett syndrome
US20180015098A1 (en) Apilimod compositions and methods for using same
JP6889493B2 (ja) 脳卒中からの回復のための方法および組成物
Milano et al. Antinociceptive action of 4-methyl-5-trifluoromethyl-5-hydroxy-4, 5-dihydro-1H-pyrazole methyl ester in models of inflammatory pain in mice
US9427439B1 (en) Methods and compositions for recovery from stroke
EA015483B1 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
US20210093586A1 (en) Method of reducing neuronal cell death with haloalkylamines
HK40012264A (en) Method of reducing neuronal cell death with haloalkylamines
AU2021383325A9 (en) Use of pridopidine and analogs for treating rett syndrome
WO2026052068A1 (zh) 药物组合物的用途
Norman et al. Zimelidine: a placebo-controlled trial in depression
TW202510885A (zh) Pde5抑制劑組合於促進神經突生長之新穎用途
Divyashree Screening of Analgesic and Anti Inflammatory activity of Vilazodone in Rodents
JP5898964B2 (ja) ロキソプロフェン又はその塩を含有する医薬組成物
WO2016192098A1 (zh) 包含阿卡波糖之医药组合物及其用于免疫调节之用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160427

RJ01 Rejection of invention patent application after publication